To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

NCT02977169 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage IIIA
Radiotherapy

Interventions

RADIATION: PORT
DRUG: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

Sponsor

Shanghai Chest Hospital